David Mccullough Email & Phone Number

Cary, North Carolina, United States

An experienced and successful biotech executive providing strategic advisory services to C-suite executives and board of directors from start-up to established companies in both the public and private sector. From drug discovery through commercialization.

Philadelphia, PA, US

Enterin, Inc. is a clinical stage biopharmaceutical company developing hormones for the treatment of neurodegenerative and metabolic disorders. ENT-01 for Parkinson’s Disease related non-motor symptoms. ENT-03 for obesity and T2D. As CEO, Mr. McCullough’s primary focus was to set the overall strategy, build an infrastructure, a BOD’s and external SAB’s to.

As part of building Merck’s US Allergy business, a strategic decision was made to create a stand-alone US entity in preparation for commercial launch. Allergopharma USA, Inc. was created under my leadership with the responsibility to operationalize NewCo and create the necessary capabilities for NDA filing and commercialization for the US territory.Led a.

Boston, Massachusetts, US

Parent company Merck and their European subsidiary Allergopharma GmbH were developing a novel Epinephrine auto-injector for treatment of anaphylaxis. Through Merck’s US subsidiary EMD Serono my responsibility was to build the US Allergy Franchise for commercialization. At the time of joining EMDS their estimated net present value of the asset was.

Led a small start-up focused on bringing HCV treatments to Egypt and Latin America where prevalence of disease is per capita the highest in the world. Shaped and implemented overall company strategy in HCV and led raise of seed capital. Led discussions with the Egyptian Health Authority, investigators, contract research organization and consultants. Led.

Durham, NC, US

Joined BioCryst as a Corporate Officer and member of the Leadership Team reporting to the CEO. Upon joining, supported CEO/Board in the restructuring of the Management Team. The company was in need of a well thought out growth strategy that would renew confidence in the company. Shortly after joining co-developed a new strategy pitched to investors and.

Darmstadt, DE

A few years prior to joining the company Merck had formed a US business EMD with a focus on in-licensing of commercial stage assets or an acquisition of an established entity. In 2002, joined EMD and began using my deep commercial and industry knowledge to contribute to those efforts making significant contributions that led to Merck achieving its goal..